Bruno Reigner - Concepedia

Author

Bruno Reigner

Roche (Switzerland)

Also Known As

B G Reigner, B REIGNER, B Reigner, B. G. Reigner, B. Reigner, B.G. Reigner, Bruno G. Reigner, Bruno Reigner

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)University of California, San Francisco Roche (United Kingdom)Beatson West of Scotland Cancer Centre La Roche College

About

Bruno Reigner is an author at Roche (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	2.1K
2	Engineering	3	3	74
3	Health Sciences	2	2	171
4	Anatomy	2	2	36
5	Natural Sciences	1	1	15

Bruno Reigner

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Johannes Sch�ller, Jim Cassidy, Étienne Dumont, Cancer Chemotherapy and Pharmacology OncologyChemoprevention StrategyGastrointestinal OncologyMedicineColorectal Cancer	2000	666
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. Melanie Mackean, André Planting, Chris Twelves, Journal of Clinical Oncology	1998	266
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. Daniel R. Budman, Neal J. Meropol, Bruno Reigner, Journal of Clinical Oncology	1998	257
Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease Iain C. Macdougall, Richard A. Robson, Sylvie Opatrná, Clinical Journal of the American Society of Nephrology HemodialysisUrologyRenal FunctionPeritoneal DialysisMedicine	2006	188
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Bruno Reigner, Jaco J. Verweij, Luc Dirix, PubMed NutritionChemoprevention StrategyFood IntakePathologyOral Administration	1998	161
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Chris Twelves, Rob Glynne‐Jones, Jim Cassidy, PubMed Hepatic DysfunctionChemoprevention StrategyPathologyPharmacotherapyTumor Biology	1999	158
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients Christopher Poole, J. Gardiner, Chris Twelves, Cancer Chemotherapy and Pharmacology UrologyMedicineMetronomic TherapyPharmacologyPharmacotherapy	2002	131
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug Ian Judson, Philip Beale, José Trigo, Investigational New Drugs Pharmacological StudyMedicine14C-labelled DrugPharmacokinetic StudyPharmacotherapy	1999	120
An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development Bruno Reigner, Peter Williams, Indra H. Patel, Clinical Pharmacokinetics Pharmacological StudyPharmacodynamicsDrug DiscoveryPharmacologyPharmacodynamic Principles	1997	119
Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients Ronald Gieschke, Hans‐Ulrich Burger, Bruno Reigner, British Journal of Clinical Pharmacology	2003	110

Page 1